Research Tracker›Biomarker Atlas›Marker Pages›Carnitine / Acylcarnitines

Carnitine / Acylcarnitines: biomarker evidence

Carnitine / Acylcarnitines appears in 1 entry of the OSMF biomarker atlas, covering Long COVID. Across those entries it is mixed in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

Long COVID

Where Carnitine / Acylcarnitines is reported

Also listed as: Fatty acid transport

ConditionDirectionCompared againstAssociated symptomsSource
Long COVID↕ inconsistenthealthy controls, recovered individuals without persistent symptomsMitochondrial fatty acid oxidationBaalbaki et al. 2025

Frequently asked questions

In which conditions is Carnitine / Acylcarnitines altered?

In the OSMF atlas Carnitine / Acylcarnitines is reported in Long COVID. It is mixed in 1 across 1 entries.

Is there a standard clinical test for Carnitine / Acylcarnitines?

The atlas entries for Carnitine / Acylcarnitines do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal Carnitine / Acylcarnitines result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Carnitine / Acylcarnitines across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/carnitine-acylcarnitines.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.